Navigation Links
Amgen Highlights Data to Be Presented at American Society for Bone and Mineral Research (ASBMR) Meeting
Date:10/14/2010

ortunity, competitive position, and success or failure of our products or product candidates.  Further, the discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations.

The scientific information discussed in this news release relating to new indications for our products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration (FDA) for the products.  The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses.  Only the FDA can determine whether the products are safe and effective for these uses. Healthcare professionals should refer to and rely upon the FDA-approved labeling for the products, and not the information discussed in this news release.

CONTACT: Amgen, Thousand Oaks Kerry Beth Daly: (516) 982-9328 (U.S. media)Arvind Sood: (805) 447-1060 (investors)(1)  Osteoporosis Fast Facts. Washington (DC): National Osteoporosis Foundation. Accessed on May 10, 2010 at http://www.nof.org.

(2)  National Osteoporosis Foundation.  http://www.nof.org. Accessed May 13, 2010.

(3)  Cooper C. The crippling consequences of fractures and their impact on quality of life. Am J Med. 1997 Aug 18;103(2A):12S-17S; discussion 17S-19S.

(4)  Burge R et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2007 Mar;22(3):465-75.

(5)  Osteoporosis Fast Facts. Washington (DC): National Osteoporosis Foundation. Accessed on April 29, 2010 at http:/
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Amgens Roger M. Perlmutter, M.D., Ph.D., Named 2009 AAAS Fellow, Recognized for Discovery, Development of Novel Medicines
2. Array BioPharma and Amgen Partner in Type 2 Diabetes
3. Amgen to Present at Lazard Capital Healthcare Conference
4. Amgen Announces Webcast of 2009 Third Quarter Financial Results
5. Amgen to Present at the Bank of America Merrill Lynch Global Healthcare Conference
6. Amgen to Present at the Morgan Stanley Global Healthcare Unplugged Conference
7. Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO)
8. Amgen to Participate in Reproductive Health Drugs Advisory Committee Meeting in August
9. Amgen Exercises Option for Exclusive License to Cytokinetics Cardiac Contractility Program That Includes CK-1827452
10. Amgen Announces Voting Results Of Annual Meeting Of Stockholders
11. Photos: Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Toronto, Canada (PRWEB) May 21, 2013 ... there is a strong push within the industry ... Development and Manufacturing Organizations and pharma companies often ... time frames. , Microtablets, developed in collaboration with ... how effective outsourcing can bring products to market ...
(Date:5/21/2013)... May 21, 2013  MacroGenics, Inc. today announced ... margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody (MAb), ... HER2 oncoprotein," will be presented at the 2013 ... Oncology during the Developmental Therapeutics - Immunotherapy Oral ... – 4:30 PM.  The presentation will describe the ...
(Date:5/21/2013)... York, NY (PRWEB) May 21, 2013 Bed ... And according to My Cleaning Products, many turn to chemical-based ... because of the health and environmental risks those solutions present, ... with Bed Bug Bully instead. , According to ... bed bugs as they used to be. It shared that ...
(Date:5/21/2013)... 2013 Inflamax scientists worked closely ... to design the study, which will provide critical ... models used in the study of allergy treatments, ... Challenge (NAC) models. Although both the models are ... date no direct comparison between the allergic responses ...
Breaking Biology Technology:The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 2New Guide to Kill Bed Bugs Published by My Cleaning Products, Company Enumerates Non-Toxic Means to Clear the Pests 3Inflamax Research selected by the Immune Tolerance Network and the National Institutes of Health to conduct a landmark clinical study on the underlying mechanisms of allergic inflammation. 2
... Scientists are using the engineering technology behind the ... models for the replacement of delicate and complex ... The researchers, combining engineering and plastic ... topological optimization to design an experimental 3-D structure ...
... IRVINE, Calif. , July 12 ... the development and commercialization of personalized DNA-based diagnostics ... completed license agreements with key Norwegian cancer researchers. ... promising genomic technologies with the intention of developing ...
... , July 12, 2010 Points to,Novel Pathway for Drug ... Abdominal Aortic Aneurysm, Heart Attack and,PAD , ... Scientists at deCODE genetics and academic ... and North America today,report the discovery of a common ...
Cached Biology Technology:High-performance engineering used to design facial bone replacements 2High-performance engineering used to design facial bone replacements 3OvaGene Oncology Licenses Gene-Based Technologies to Develop Novel Endometrial and Cervical Cancer Assays 2OvaGene Oncology Licenses Gene-Based Technologies to Develop Novel Endometrial and Cervical Cancer Assays 3OvaGene Oncology Licenses Gene-Based Technologies to Develop Novel Endometrial and Cervical Cancer Assays 4deCODE Discovers Genetic Risk Factor Linking Susceptibility to Four Major Vascular Diseases 2deCODE Discovers Genetic Risk Factor Linking Susceptibility to Four Major Vascular Diseases 3deCODE Discovers Genetic Risk Factor Linking Susceptibility to Four Major Vascular Diseases 4
(Date:5/21/2013)... have developed a new method for delivering molecules ... the cell surface. The technique could find applications ... fields. , Bulk electroporation a technique used ... in the cell membrane that are caused by ... increasingly popular method of cell transfection. (Cell transfection ...
(Date:5/21/2013)... the University of Illinois at Chicago College of Medicine will ... fat -- its main energy source -- and how changes ... a new $2 million, 4-year grant from the National Heart, ... how it uses fuel for energy. These changes may play ... are different in men and women, says E. Douglas Lewandowski, ...
(Date:5/21/2013)... of biomass experts , Where? Copenhagen, ... 03-07 June 2013 , Why? ... assessment, market and policy developments, manufacturing and installation, drawing ... benefiting from its 2013 edition from a record of ... countries, more than 240 plenary and oral presentations, more ...
Breaking Biology News(10 mins):Single-cell transfection tool enables added control for biological studies 2Do men's and women's hearts burn fuel differently? 221st European Biomass Conference and Exhibition 221st European Biomass Conference and Exhibition 321st European Biomass Conference and Exhibition 4
... a gas they also produce naturally as a hormone, the result ... and fading in the case of flowers all of which ... plants with products available in the market today, such as EthylBloc ... for fruits and vegetables, that contain a compound that blocks ...
... mechanism of action of genes has been hampered by the ... is true for even the most common class of cancer-associated ... events in cells by phosphorylating and modulating the activity of ... efforts that up to a quarter of kinases may play ...
... TAMPA, Fla., May 1 Stinger Systems, Inc. ... today announced,that it had reached a settlement agreement ... Inc. said it settled the matter without admitting ... barring future,violations. Stinger Systems, Inc. also said that ...
Cached Biology News:A new idea for how anti-aging products delay ripening of fruit and wilting of flowers 2A new idea for how anti-aging products delay ripening of fruit and wilting of flowers 3
Anti-Tissue Trans-glutaminase (IgA) EIA Sample Size: 10 l...
... a new technology for sensitive detection ... amounts of DNA (5). This process ... modify the DNA, followed by PCR ... distinguish methylated from unmethylated DNA. The ...
... Incubator/Shaker HT is designed for ... Incubator/Shaker HT is ideal for ... and primer extension assays. iEMS ... a one-cabinet model, allowing the ...
... atlantica Description: Beta-Agarase is useful in ... low-melting-temperature agarose. Beta-Agarase digests the agarose ... Friendly Properties: Heat Inactivation: 65C, 15 ... pH: 6.5 Purity: Tested for contaminating ...
Biology Products: